• LAST PRICE
    3.4900
  • TODAY'S CHANGE (%)
    Trending Up0.2800 (8.7227%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    3.2900 / 3.2100
  • Day Range
    Low 3.1600
    High 3.6500
  • 52 Week Range
    Low 1.8000
    High 6.9300
  • Volume
    19,929
    average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.21
TimeVolumeNRXS
09:35 ET1003.29
09:37 ET3003.25
10:02 ET4003.28
10:58 ET23003.25
11:09 ET5503.16
11:16 ET1003.21
11:18 ET5003.26
11:43 ET11253.42
11:54 ET1003.31
11:57 ET2003.33
12:06 ET2003.38
12:21 ET1003.33
01:31 ET7003.37
02:14 ET2003.38
02:18 ET2003.38
02:39 ET3003.49
02:57 ET3003.37
03:14 ET3003.49
03:24 ET2003.35
03:44 ET16003.37
03:48 ET24003.62
03:50 ET2003.65
03:51 ET19383.5
03:53 ET8003.49
03:55 ET13003.49
04:00 ET03.49
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNRXS
Neuraxis Inc
16.9M
-1.2x
---
United StatesNTRB
Nutriband Inc
19.1M
-3.6x
---
United StatesPOAI
Predictive Oncology Inc
14.9M
-0.7x
---
United StatesBMRA
Biomerica Inc
18.2M
-3.3x
---
United StatesCTGL
Citrine Global Corp
18.3M
-7.6x
---
United StatesPETV
PetVivo Holdings Inc
20.1M
-1.4x
---
As of 2024-02-24

Company Information

Neuraxis, Inc. is a growth-stage company that is primarily focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The Company is involved in advancing the science with its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The Company’s pipeline B-Stim device is used for the indication of functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children. The IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The United States Food and Drug Administration (FDA) pipeline has indications, including chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome.

Contact Information

Headquarters
11611 N. Meridian St, Suite 330CARMEL, IN, United States 46032
Phone
812-689-0791
Fax
845-818-3588

Executives

Independent Chairman of the Board
Bradley Watkins
President, Chief Executive Officer, Director
Brian Carrico
Director - Innovation, Founder, Director
Christopher Brown
Chief Financial Officer
Timothy Henrichs
Chief Operating Officer
Dan Clarence

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$17.0M
Revenue (TTM)
$2.5M
Shares Outstanding
5.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.81
Book Value
$-0.91
P/E Ratio
-1.2x
Price/Sales (TTM)
6.7
Price/Cash Flow (TTM)
---
Operating Margin
-237.15%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.